PlexBio Receives FDA Certification of IntelliPrep TRIO System, Expanding into Korea Market to Advance Molecular Testing Automation

    With the rise of precision medicine globally, the demand for molecular testing in cancer genetics is rapidly growing. It is crucial to enhance testing accuracy with a complete and efficient sample preparation system. To address the market needs, PlexBio has developed an innovative automated sample preparation system, the "IntelliPrep TRIO 240" which can automatically extract nucleic acids from various specimen types (tissue, blood, saliva, and pleural effusion), perform nucleic acid quantification, and automatically prepare PCR reactions based on quantification results.
    PlexBio Co., Ltd. (TPEx: 6572) announced today that its innovative IntelliPrep TRIO 240 automated sample preparation system has received FDA certification this month. Additionally, PlexBio has signed a distribution agreement with Korean distributor Chris & Paul, marking the successful entry of IntelliPrep TRIO 240 into the Korean market. Diagenex will be responsible for promotion and sales, bringing breakthrough innovation into Korea's molecular testing market.
    The IntelliPrep TRIO 240 system utilizes unique patented magnetic bead liquid handling technology, not only offering a one-stop solution for nucleic acid extraction, DNA quantification, and PCR reaction preparation. This system is especially effective for FFPE (formalin-fixed, paraffin-embedded) cancer tissue samples, delivering complete and efficient nucleic acid extraction without lengthy pre-treatment, making pathology department testing procedures faster and more precise. Diagenex expressed high expectations for the product: "IntelliPrep TRIO 240's advanced automated technology eliminates the need for sample pre-processing steps, reducing tedious manual sample handling and time, making nucleic acid extraction more convenient. It also supports various downstream testing applications, including ddPCR, NGS, and qPCR, providing customers with more flexible options."
    Dr. Dean Tsao, Chairman and CEO of PlexBio remarked: "We are honored that the IntelliPrep TRIO 240 has received FDA approval and be partnering with Diagenex. This is a significant milestone, demonstrating the system’s efficient and accurate sample processing capabilities that support extensive downstream applications to meet diverse laboratory needs. We look forward to a close collaboration with Diagenex that will bring PlexBio's innovative technology to more medical laboratories and advancing precision medicine in Korea."
    Diagenex CEO Kim In-taek highly praised the cooperation with PlexBio: "IntelliPrep TRIO 240's innovative automated workflow provides our clinical customers with a highly efficient sample preparation system, offering flexible and reliable options for clinical laboratories, enabling clinical pathologists to support downstream genetic analysis more quickly and precisely for patients."
    This partnership in Korea signifies the close alignment between PlexBio's technological innovations and the growing international demand for advanced diagnostics. PlexBio will deepen its presence in the Korean market with Diagenex, bringing more efficient and accurate technologies to local healthcare institutions and supporting the rapid development of precision medicine in Korea.